Acute non-lymphocytic leukaemia (ANLL)occurs with increased frequency in women with previously diagnosed breast cancer. Adjuvant radiotherapy and chemotherapy are related to this increase. We studied the interrelationships among age at breast cancer diagnosis, interval to ANLL diagnosis, and survival in 54 women of whom 11 were from Kansas and 43 were from two other published series. Median age at breast cancer diagnosis was 50.5 years, median interval to ANLL diagnosis was 4.8 years, and median survival after ANLL diagnosis was 2.2 months. Increasing age was associated with a decrease of the interval to ANLL diagnosis just short of statistical significance (P=0.0591). There was no association of survival with either age or the interval to ANLL diagnosis. With an increase in the use of adjuvant therapy in breast cancer there is a need to identify women at greatest risk of subsequently developing ANLL, at present not possible.
Introduction
An association of primary soft tissue malignancies and subsequent acute leukaemia has frequently been reported l -20 • Exact mechanisms for this have not been established but two major theories have suggested that: (1) there exists a genetic predisposition to the development of cancer in general and this may be mediated by an oncogenic stimulus; and (2) second malignancies are directly related to the prior treatment of the first neoplasm. The association of primary breast cancer with subsequent second haematologic malignancy is well-known.
Breast carcinoma is unique in that many patients survive for long periods following initial treatment of their disease. This allows second malignancies to be recognized prior to the patient's death. Several investigators have evaluated the relationship between breast cancer and the development of acute leukaemia. This topic has received increasing attention in the literature since the late 1960s. Carey and associates noted that the incidence of acute myelogenous leukaemia (AML) after breast cancer was 30 times greater than expected in the general population'. Several studies since then have concluded that breast cancer patients are at an increased risk for acute leukaemia following chemotherapy, radiotherapy, or a combination thereof 2-5 • Several other studies, however, have not found an increased risk 6 -9 • A comprehensive review of the literature by Rosner and associates in 1978 found only 54 reported cases of acute leukaemia following breast cancer. Their study added 24 new cases with a mean interval of6.9 years between the two diagnoses. The authors concluded that most of the acute leukaemia cases in patients receiving chemotherapy occurred in those treated with aggressive multi-drug regimens", Ershler and associates studied the morphological and cytogenetic features of acute non-lymphocytic leukaemia (ANLL) in 11 breast cancer patients and found that those with characteristics of de novo ANLL could expect to have a more favourable response to anti-leukaemic therapy than those patients who had treatment-related ANLUo. Refractoriness to conventional therapy has been well-documented in ANLL following previous cancer treatment lll 4 . Indeed, most of these patients die in less than one year following diagnosiss-'", By comparison, most centres report at least a 50% complete remission rate in de novo ANLL patients'", A recent review showed a mean survival of less than 6 months for 75 patients with treatment related acute leukaemia. There were 17 responders to chemotherapy with the longest survival being 29 months". A report by Kingsley identified two such patients who survived 62 months and 84 months. Both had received aggressive induction therapy!", Fisher and associates from the National Surgical Adjuvant Breast and Bowel Project in Pittsburgh studied over 8000 women with primary breast carcinoma who participated in seven trials evaluating adjuvant chemotherapy. Since leukaemia occurred in only three women who were treated by operation alone, the authors determined that leukaemia is not an important factor in the natural history of breast cancer. The study concluded that there was a significantly increased risk of acute leukaemia following postoperative regional radiation and adjuvant chemotherapy. Even though the relative risk is increased the authors thought the benefit from adjuvant chemotherapy for breast cancer exceeds the risk of acute leukaemia", Although most studies in the literature were based on case reports or small groups of patients, these observations give important insight into this disease. Brenner et al. found that acute leukaemia developed earlier in patients treated by chemotherapy with or without regional radiation than in patients treated by radiotherapy alone'", A study by Lemer'" found patients who developed clinical signs of acute myelogenous leukaemia only after completion of longterm chemotherapy and not before therapy was discontinued. In another study, four patients with inoperable or metastatic breast cancer who had been well-controlled with chemotherapy for several years, died from ANLL20.
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Results
There were 54 ANLL cases in the three groups: Kansas 11, Pittsburgh 32, and Wisconsin 11. As shown in Table 1 the mean age at diagnosis of breast cancer was 52.5 years, with a median of 50.5 years, and a range of 30-75 years. The mean interval between the diagnosis of breast cancer and ANLL was 5.5 years with a median of 4.8 years and a range of 0-29.4 years. The mean survival was 5.7 months with a median of 2.2 months and a range of 0.1-61.5 months. Table 2 shows the correlations between age at diagnosis of breast cancer, interval to diagnosis of ANLL, and survival after that diagnosis. Increasing age is associated with decreasing interval to diagnosis of ANLL which approaches significance (P=0.0591). However, the correlation of survival to age at breast cancer diagnosis and interval to ANLL diagnosis, though negative, do not approach statistical significance.
In Figure 1 , a Kaplan-Meier plot shows the survival experience of all 54 patients with most dead by one year after ANLL diagnosis. Actually 20 (37%) lived longer than 6 months, and these patients were not different from the group at large in respect to age at breast cancer diagnosis or interval to ANLL diagnosis.
Discussion
Breast cancer is a common disease. Long survival after adjuvant treatment with radiation and chemotherapy is the rule. Second malignancies in treated breast cancer patients are by no means rare and acute leukaemia is now recognized as both a major variety of second malignancy in this group of patients and a consequence of adjuvant therapy in a few", In analysing the pooled data of three series it can be observed that the typical breast cancer patient who will subsequently develop ANLL is a woman in her early 50s whose acute leukaemia will be diagnosed 4-5 years after her diagnosis of breast cancer. She will be dead within several months. Her survival will bear no relation to her age at diagnosis of breast cancer or the interval between breast cancer and acute leukaemia diagnoses. However, in general, the older she is the shorter will be the interval between breast cancer and acute leukaemia diagnosis. Materials and methods Patient registrations were identified from the Cancer Data Service, the Tumor Registry for the State of Kansas. A total of 20 504 women with a diagnosis of breast cancer were registered. Of these women, 16 were found to have a subsequent diagnosis of acute leukaemia and 11 of these had ANLL; one had cervical cancer first, followed by breast cancer and ANLL. One patient had breast cancer followed by ovarian cancer with subsequent ANLL. Three variables were analysed in these women: age at diagnosis of breast cancer, interval in years to diagnosis of ANLL, and the survival in months following the diagnosis of ANLL. Due to the incompleteness of some records, a further breakdown by mode of breast cancer therapy was not attempted. Additional information was utilized from the data published by Fisher'' and Ershler-", The same three variables were available for analysis on these additional 43 patients with breast cancer and subsequent ANLL. Correlations were made for each group separately and for all three groups together. Standard descriptive statistical information was obtained from each set of data. An analysis of longterm survivors was also undertaken and compared to the group. between age of diagnosis of breast cancer, the interval before the diagnosis of ANLL is made, and the subsequent survival. In the present study, we examine these relationships with data from our own centre as well as from two other studies from the literature.
It would be beneficial if women at increased risk of acute leukaemia could be identified at the time adjuvant breast cancer therapy is being considered as it seems likely that adjuvant radiotherapy and chemotherapy will be used with increasing frequency in the future 2 1 • 22 • However, this does not seem possible yet. Even age is not a predictor of the likelihood of subsequent development of acute leukaemia in this setting. We found the age at diagnosis of breast cancer followed by leukaemia to range from 30 to 75 years. Fisher et ai. 3 found the increase in acute leukaemia in this breast cancer population not to be age related, though the myeloproliferative syndrome seemed to be confined to older women.
